The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Abstract
Inosine modulates antitumor immunity: Checkpoint blockade immunotherapy harnesses the immune system to kill cancer cells and has been used with great success to treat certain tumors, but not all cancer patients respond. The efficacy of checkpoint blockade immunotherapy has been shown to depend on the presence of distinct, beneficial bacteria residing in the gut of patients, but how the microbiome mediates such beneficial effects is unclear. Mager et al. found that specific bacteria produce a metabolite called inosine that enhances the effect of checkpoint blockade immunotherapy (see the Perspective by Shaikh and Sears). In mouse models, inosine, together with proinflammatory stimuli and immunotherapy, strongly enhanced the antitumor capacities of T cells in multiple tumor types, including colorectal cancer, bladder cancer, and melanoma. Science , this issue p. 1481 ; see also p. 1427
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inosine, the purine metabolite of Akkermansia muciniphila and Bifidobacterium pseudolongum (B. pseudolongum), plays a vital role in improving the efficacy of ICI [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The inosine-A2AR-cAMP-PKA signaling cascade led to the phosphorylation of cAMP response element-binding protein (pCREB), which upregulated IL12Rβ2 and IFNγ transcription and promoted Th1-cell differentiation and accumulation in the TME [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The gut microbial metabolite inosine could improve the efficacy of ICI by acting on adenosine 2A receptor (A2AR) on T lymphocytes in intestinal cancer, bladder cancer, and melanoma mouse models [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“Moreover, specific gut microbes, such as Bifidobacterium [16, 33, 51, 141], Akkermansia [31, 38], Enterococcus [15, 33, 141], Faecalibacterium [49, 142], and Ruminococcaceae [32], play the role of immune adjuvants in ICI immunotherapy.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“for example, anti-CTLA-4 appears to modify gut barrier integrity 51 and thus could feasibly change microbial compositions”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
16S ribosomal DNA amplification for phylogenetic study
Weisburg, W. G., Barns, S. M., Pelletier, D. A., & Lane, D. J. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.2.697-703.1991 · Cited by 11,934
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cited by
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
“Other immunoregulatory molecules produced by specific bacterial subspecies are being identified and functionally evaluated, including bacteria-produced inosine, a rate-limiting metabolite for T-cell activity (100).”
BackgroundHiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
“Anti–CTLA-4–induced gut barrier dysfunction was also critical for systemic translocation of Bifidobacterium-derived inosine, in turn promoting TH1 activation and antitumor immunity by agonizing T cell–specific adenosine 2A receptor (A2AR) signaling in the context of DC costimulation (93).”
BackgroundAkkermansia muciniphila: paradigm for next-generation beneficial microorganisms
Cani, P. D., Depommier, C., Derrien, M., Everard, A., & de Vos, W. M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00631-9 · Cited by 1,192
Luu, M., Riester, Z., Baldrich, A., Reichardt, N., Yuille, S., Busetti, A., Klein, M., Wempe, A., Leister, H., Raifer, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24331-1 · Cited by 771
Short-chain fatty acids in diseases
Zhang, D., Jian, Y.-P., Zhang, Y.-N., Li, Y., Gu, L.-T., Sun, H.-H., Liu, M.-D., Zhou, H.-L., Wang, Y.-S., & Xu, Z.-X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01219-9 · Cited by 718
“The abundance of Escherichia coli and Bacteroides fragilis is reportedly higher in the intestines of patients with CRC, whereas the abundance of typical SCFA-producing bacteria, such as A. muciniphila, are significantly reduced (Table 2) [106, 107].”
BackgroundGut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 721
Zhou, J., Li, M., Chen, Q., Li, X., Chen, L., Dong, Z., Zhu, W., Yang, Y., Liu, Z., & Chen, Q. (2022) · Nature Communications · doi:10.1038/s41467-022-31171-0 · Cited by 695
Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment
Lam, K. C., Araya, R. E., Huang, A., Chen, Q., Di Modica, M., Rodrigues, R. R., Lopès, A., Johnson, S. B., Schwarz, B., Bohrnsen, E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.019 · Cited by 604
Cullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
Cancer stem cell–immune cell crosstalk in tumour progression
Bayik, D., & Lathia, J. D. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00366-w · Cited by 561
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Turning cold tumors hot: from molecular mechanisms to clinical applications
Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534
Targeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
(2022) · doi:10.1186/s13045-022-01273-9 · Cited by 495
“pseudolongum), plays a vital role in improving the efficacy of ICI [51].”
BackgroundInfluentialResistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
CD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 449
Jiang, S.-S., Xie, Y.-L., Xiao, X.-Y., Kang, Z.-R., Lin, X.-L., Zhang, L., Li, C.-S., Qian, Y., Xu, P.-P., Leng, X.-X., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.04.010 · Cited by 419
Immunotherapy in colorectal cancer: current achievements and future perspective
Fan, A., Wang, B., Wang, X., Nie, Y., Fan, D., Zhao, X., & Lu, Y. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64077 · Cited by 410
“Gut microbiota have large effect on the efficacy of immunotherapies in multiple cancers, and the composition of the intestinal microbiome could be a potential predictor of the efficacy of ICIs [82-85].”
BackgroundWang, H., Rong, X., Zhao, G., Zhou, Y., Xiao, Y., Ma, D., Jin, X., Wu, Y., Yan, Y., Yang, H., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.010 · Cited by 411
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Matson, V., Chervin, C. S., & Gajewski, T. F. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.041 · Cited by 385
Bifidobacterium mechanisms of immune modulation and tolerance
Gavzy, S. J., Kensiski, A., Lee, Z. L., Mongodin, E. F., Ma, B., & Bromberg, J. S. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2291164 · Cited by 343
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
“In fact, inosine is an immunotherapypromoting metabolite and has been experimentally shown to have an effect on colon cancer, bladder cancer and melanoma.(257) Mechanistically, inosine triggers the activation of Th1 cells by regulating T-cell-specific A2AR signaling.”
BackgroundMirji, G., Worth, A., Bhat, S. A., El Sayed, M., Kannan, T., Goldman, A. R., Tang, H.-Y., Liu, Q., Auslander, N., Dang, C. V., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn0704 · Cited by 327
“The gut microbiome produces a variety of metabolites in the process of degrading dietary factors (15); some of these can trigger inflammatory responses and thus contribute to regulating immune function and disease processes (16, 17).”
BackgroundFong, W., Li, Q., Ji, F., Liang, W., Lau, H. C. H., Kang, X., Liu, W., To, K. K.-W., Zuo, Z., Li, X., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-329543 · Cited by 312
Metabolic adaptation of lymphocytes in immunity and disease
Chapman, N. M., & Chi, H. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.012 · Cited by 305
“Also, selective nutrients or metabolic pathways can functionally compensate for glucose metabolism in certain environments in vivo (Mager et al., 2020; Wang et al., 2020b; Wu et al., 2020b).”
BackgroundGut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
Chrysostomou, D., Roberts, L. A., Marchesi, J. R., & Kinross, J. M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.10.018 · Cited by 283
Targeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Chen, Y., Yang, S., Tavormina, J., Tampe, D., Zeisberg, M., Wang, H., Mahadevan, K. K., Wu, C.-J., Sugimoto, H., Chang, C.-C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.011 · Cited by 289
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Inflammation: the incubator of the tumor microenvironment
Denk, D., & Greten, F. R. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.07.002 · Cited by 273
Intratumoural microbiota: a new frontier in cancer development and therapy
Cao, Y., Xia, H., Tan, X., Shi, C., Ma, Y., Meng, D., Zhou, M., Lv, Z., Wang, S., & Jin, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01693-0 · Cited by 253
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer
Wang, X., Fang, Y., Liang, W., Wong, C. C., Qin, H., Gao, Y., Liang, M., Song, L., Zhang, Y., Fan, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.019 · Cited by 247
Simpson, R. C., Shanahan, E. R., Batten, M., Reijers, I. L. M., Read, M., Silva, I. P., Versluis, J. M., Ribeiro, R., Angelatos, A. S., Tan, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01965-2 · Cited by 256
Stein-Thoeringer, C. K., Saini, N. Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U., Fante, M. A., Schmidt, S., Hayase, E., Hayase, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02234-6 · Cited by 255
Crosstalk between Gut Microbiota and Host Immunity: Impact on Inflammation and Immunotherapy
Campbell, C., Kandalgaonkar, M. R., Golonka, R. M., Yeoh, B. S., Vijay-Kumar, M., & Saha, P. (2023) · Biomedicines · doi:10.3390/biomedicines11020294 · Cited by 243
“Inosine, which is produced by Bifidobacterium pseudolongum and Akkermansia muciniphila, also promoted anti-CTLA-4 and anti-PD-L1 therapy by activating T cells [213].”
BackgroundLi, D., Feng, Y., Tian, M., Ji, J., Hu, X., & Chen, F. (2021) · Microbiome · doi:10.1186/s40168-021-01028-7 · Cited by 249
“checkpoint blockade immunotherapy via activation of antitumor T cells [22].”
BackgroundResultPharmacogenomics: Driving Personalized Medicine
Sadee, W., Wang, D., Hartmann, K., & Toland, A. E. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000810 · Cited by 235
A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Yang, Q., Wang, B., Zheng, Q., Li, H., Meng, X., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202207366 · Cited by 240
Li, Z., Wang, Y., Liu, J., Rawding, P., Bu, J., Hong, S., & Hu, Q. (2021) · Advanced Materials · doi:10.1002/adma.202102580 · Cited by 244
The cutting-edge progress of immune-checkpoint blockade in lung cancer
Zhou, F., Qiao, M., & Zhou, C. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00577-5 · Cited by 231
“recently uncovered the underlying mechanisms of the microbiome in modulating the antitumor effect of ICIs and found that Bifidobacterium pseudolongum enhances the antitumor immunity of CTLA-4 blockade through the metabolite inosine and was dependent on T cell-specific adenosine 2A receptor signaling.(176) These findin…”
BackgroundCRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Giuffrida, L., Sek, K., Henderson, M. A., Lai, J., Chen, A. X. Y., Meyran, D., Todd, K. L., Petley, E. V., Mardiana, S., Mølck, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23331-5 · Cited by 226
Zhang, S.-L., Mao, Y.-Q., Zhang, Z.-Y., Li, Z.-M., Kong, C.-Y., Chen, H.-L., Cai, P.-R., Han, B., Ye, T., & Wang, L.-S. (2021) · Theranostics · doi:10.7150/thno.54476 · Cited by 224
“Recently, studies of various tumor types have reported that the gut microbiota is a crucial factor associated with efficacy of cancer immunotherapy in both animal models and humans [7-11].”
BackgroundResultInfluentialThe promise of the gut microbiome as part of individualized treatment strategies
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00499-1 · Cited by 217
The Current and Future Perspectives of Postbiotics
Liang, B., & Xing, D. (2023) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-023-10045-x · Cited by 192
“recently focused on a microbiome-derived metabolite, inosine, that enhances the efficacy of cancer immunotherapy [86].”
BackgroundDysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer
Goc, J., Lv, M., Bessman, N. J., Flamar, A.-L., Sahota, S., Suzuki, H., Teng, F., Putzel, G. G., Eberl, G., Withers, D. R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.029 · Cited by 212
Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential
Xiao, Y.-L., Gong, Y., Qi, Y.-J., Shao, Z.-M., & Jiang, Y.-Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01771-x · Cited by 202
“287 Inosine is instrumental in enhancing antitumor therapy by serving as a carbon source for CD8 + T cells in glucose-restricted microenvironments, facilitating their growth and optimal functioning.”
BackgroundDerosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.029 · Cited by 198
Gut bacterial nutrient preferences quantified in vivo
Zeng, X., Xing, X., Gupta, M., Keber, F. C., Lopez, J. G., Lee, Y.-C. J., Roichman, A., Wang, L., Neinast, M. D., Donia, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.07.020 · Cited by 198
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Wu, H.-L., Gong, Y., Ji, P., Xie, Y.-F., Jiang, Y.-Z., & Liu, G.-Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01263-x · Cited by 186
“Several microbes could act on the adenosine pathway to affect cancer immunity and enhance the efficacy of immune checkpoint blockage (ICB) therapies in animal models [5].”
BackgroundInfluentialTargeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
Park, J. S., Gazzaniga, F. S., Wu, M., Luthens, A. K., Gillis, J., Zheng, W., LaFleur, M. W., Johnson, S. B., Morad, G., Park, E. M., et al. (2023) · Nature · doi:10.1038/s41586-023-06026-3 · Cited by 191
Critical role of the gut microbiota in immune responses and cancer immunotherapy
Li, Z., Xiong, W., Liang, Z., Wang, J., Zeng, Z., Kołat, D., Li, X., Zhou, D., Xu, X., & Zhao, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01541-w · Cited by 176
“Activation of the inosine-A2AR-cAMP-PKA signaling pathway leads to phosphorylation of the transcription factor cAMP response element–binding protein (CREB) [300].”
BackgroundNew Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries
Jain, T., Sharma, P., Are, A. C., Vickers, S. M., & Dudeja, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.622064 · Cited by 183
Metabolic programming in dendritic cells tailors immune responses and homeostasis
Møller, S. H., Wang, L., & Ho, P.-C. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00753-1 · Cited by 169
Strategies for the development of metalloimmunotherapies
Sun, X., Zhou, X., Shi, X., Abed, O. A., An, X., Lei, Y. L., & Moon, J. J. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01221-7 · Cited by 163
“The mechanisms behind the cross-talk between the immune system and microbiota commonly involve various metabolites 83–85 .”
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Arafat Hossain, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 178
Inosine induces stemness features in CAR-T cells and enhances potency
Klysz, D. D., Fowler, C., Malipatlolla, M., Stuani, L., Freitas, K. A., Chen, Y., Meier, S., Daniel, B., Sandor, K., Xu, P., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.002 · Cited by 171
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
Oster, P., Vaillant, L., Riva, E., McMillan, B., Begka, C., Truntzer, C., Richard, C., Leblond, M. M., Messaoudene, M., Machremi, E., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-323392 · Cited by 176
“25 Remarkably, the number of colon tumours in non-infected mice undergoing anti-CTLA4 treatment was significantly lower than those of H. pylori - infected mice (figure 1F).”
Vatanen, T., Jabbar, K. S., Ruohtula, T., Honkanen, J., Avila-Pacheco, J., Siljander, H., Stražar, M., Oikarinen, S., Hyöty, H., Ilonen, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.11.023 · Cited by 179
Gut microbiome in modulating immune checkpoint inhibitors
Li, X., Zhang, S., Guo, G., Han, J., & Yu, J. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104163 · Cited by 168
Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
Derosa, L., Routy, B., Desilets, A., Daillère, R., Terrisse, S., Kroemer, G., & Zitvogel, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0236 · Cited by 170
Wang, F., He, M.-M., Yao, Y.-C., Zhao, X., Wang, Z.-Q., Jin, Y., Luo, H.-Y., Li, J.-B., Wang, F.-H., Qiu, M.-Z., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100383 · Cited by 167
Indole-3-Acetic Acid Alters Intestinal Microbiota and Alleviates Ankylosing Spondylitis in Mice
Shen, J., Yang, L., You, K., Chen, T., Su, Z., Cui, Z., Wang, M., Zhang, W., Liu, B., Zhou, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.762580 · Cited by 166
“Bifidobacterium pseudolongum, a member of the genus Bifidobacterium, is a key commensal intestinal bacterial species with immunomodulatory capacity (100) and is associated with positive health effects, including increased gut barrier integrity and reduced inflammation (101).”
BackgroundModulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Kang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101478 · Cited by 198
“19 The microbe-derived metabolic product of tryptophan metabolism, an essential amino acid, can also influence the TME.”
BackgroundInfluentialColorectal cancer: the facts in the case of the microbiota
Clay, S. L., Fonseca-Pereira, D., & Garrett, W. S. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155101 · Cited by 166
“In addition to the heterotopic MC38 model, Mager et al. tested the effect of their ICI-promoting strains in two genetic models of CRC, one MSIhi and the other MSS (121).”
BackgroundInfluentialA gut microbial signature for combination immune checkpoint blockade across cancer types
Gunjur, A., Shao, Y., Rozday, T., Klein, O., Mu, A., Haak, B. W., Markman, B., Kee, D., Carlino, M. S., Underhill, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02823-z · Cited by 165
“Furthermore, the addition of anti-CTLA-4 has a profound effect on gut barrier permeability 50,51 , potentially changing the influence of the gut microbiome on ICB response.”
Guo, W., Xiang, Q., Mao, B., Tang, X., Cui, S., Li, X., Zhao, J., Zhang, H., & Chen, W. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c01781 · Cited by 164
Gut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 194
Clinical translation of advanced colonic drug delivery technologies
Awad, A., Madla, C. M., McCoubrey, L. E., Ferraro, F., Gavins, F. K. H., Buanz, A. B. M., Gaisford, S., Orlu, M., Siepmann, F., Siepmann, J., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114076 · Cited by 183
Sun, Y., Zhang, X., Hang, D., Lau, H. C.-H., Du, J., Liu, C., Xie, M., Pan, Y., Wang, L., Liang, C., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.07.005 · Cited by 179
Tweak to Treat: Reprograming Bacteria for Cancer Treatment
Sieow, B. F.-L., Wun, K. S., Yong, W. P., Hwang, I. Y., & Chang, M. W. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2020.11.004 · Cited by 158
Zheng, D., Deng, W., Song, W., Wu, C., Liu, J., Hong, S., Zhuang, Z., Cheng, H. L., Sun, Z., & Zhang, X. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00807-9 · Cited by 166
Dietary Lactobacillus -Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy
Kawanabe-Matsuda, H., Takeda, K., Nakamura, M., Makino, S., Karasaki, T., Kakimi, K., Nishimukai, M., Ohno, T., Omi, J., Kano, K., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0929 · Cited by 166
“These effects were postulated to be mediated by bacterial-derived metabolites or cell wall components [such as short chain fatty acids (14), inosine (15), and peptidoglycan (16)].”
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Vitamin D regulates microbiome-dependent cancer immunity
Giampazolias, E., Pereira da Costa, M., Lam, K. C., Lim, K. H. J., Cardoso, A., Piot, C., Chakravarty, P., Blasche, S., Patel, S., Biram, A., et al. (2024) · Science · doi:10.1126/science.adh7954 · Cited by 151
The gut microbiome: what the oncologist ought to know
Lee, K. A., Luong, M., Shaw, H. M., Nathan, P., Bataille, V. A., & Spector, T. D. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01467-x · Cited by 159
“discovered that Bifidobacterium pseudolongum produced a metabolite called inosine, which enhanced the effect of ICI in mouse models [70].”
BackgroundZhang, C., Huang, J., Zeng, Z., He, S., Cheng, P., Li, J., & Pu, K. (2022) · Nature Communications · doi:10.1038/s41467-022-31044-6 · Cited by 160
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Zhang, M., Liu, J., & Xia, Q. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00442-x · Cited by 167
Lau, H. C.-H., Zhang, X., Ji, F., Lin, Y., Liang, W., Li, Q., Chen, D., Fong, W., Kang, X., Liu, W., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2023.104952 · Cited by 172
“8,9 Probiotics also showed promising therapeutic potential against NAFLD and NASH, 10 yet their role in NAFLD-HCC is unclear.”
Role of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
“Conversely, however, tryptophan metab olites produced by indole-producing bacteria including Lactobacillus spp. have been shown to suppress ICB responses in mice with pancreatic ductal adenocarcinoma (PDAC) by inducing AHR signalling in macrophages 105 .”
InfluentialHayase, E., & Jenq, R. R. (2021) · Genome Medicine · doi:10.1186/s13073-021-00923-w · Cited by 145
“identified a high abundance of the purine metabolite inosine in the serum and cecal contents of Bifidobacterium pseudolongum-monocolonized GF mice who exhibited enhanced anti-tumor responses by ICIs [54].”
BackgroundT cell dysfunction and therapeutic intervention in cancer
Zebley, C. C., Zehn, D., Gottschalk, S. M., & Chi, H. (2024) · Nature Immunology · doi:10.1038/s41590-024-01896-9 · Cited by 157
“Inosine, a nucleoside that can be derived from the microbiome, has been shown to have potent immunostimulatory effects on T cells that improve anti-tumor function 111–113 .”
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
“Mager et al.167 identified the first immunostimulatory oncometabolite produced in the gut by Bifidobacterium spp. (such as B. pseudolongum) among other commensals.”
BackgroundExploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy
Qiu, Q., Lin, Y., Ma, Y., Li, X., Liang, J. B., Chen, Z., Liu, K., Huang, Y., Luo, H., Huang, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612202 · Cited by 151
Ma, J., Huang, L., Hu, D., Zeng, S., Han, Y., & Shen, H. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02128-w · Cited by 152
“With the costimulatory effects from dendritic cells, inosine induces naïve T cells to differentiate into CD4+Th1 [33].”
BackgroundIntestinal bacteria and colorectal cancer: etiology and treatment
Dougherty, M. W., & Jobin, C. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185028 · Cited by 159
The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy
(2021) · doi:10.3389/fonc.2021.720842 · Cited by 136
In situ targeted base editing of bacteria in the mouse gut
Brödel, A. K., Charpenay, L. H., Galtier, M., Fuche, F. J., Terrasse, R., Poquet, C., Havránek, J., Pignotti, S., Krawczyk, A. O., Arraou, M., et al. (2024) · Nature · doi:10.1038/s41586-024-07681-w · Cited by 158
“Bacteria can affect the success of immunotherapies 3,4 , bacterial proteins are involved in neurodegenerative 5 and autoimmune diseases 6–8 , bacterial toxins can drive a range of acute and chronic diseases including cancer 9,10 and bacteria can modify or sequester drugs affecting the effectiveness…”
Choi, Y., Lichterman, J. N., Coughlin, L. A., Poulides, N., Li, W., Del Valle, P., Palmer, S. N., Gan, S., Kim, J., Zhan, X., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abo2003 · Cited by 132
“Gut bacteria-derived metabolites (e.g. inosine (9), c-di-AMP (20) or short-chain fatty acids (3, 21)) or pathogen-associated molecular patterns (e.g. muramyl peptide (22)) can enhance anti-cancer T cell responses.”
InfluentialLagoumintzis, G., & Patrinos, G. P. (2023) · Human Genomics · doi:10.1186/s40246-023-00561-w · Cited by 132
Li, Z., Zhang, Y., Hong, W., Wang, B., Chen, Y., Yang, P., Zhou, J., Fan, J., Zeng, Z., & Du, S. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2119055 · Cited by 142
“Specific members of the gut microbiota interact with immune cells to promote tumor clearance, suppress cancer cell metastasis, and inhibit chronic inflammation.(12) Gut microbiota regulate systemic antiviral immunity via the cGAS– STING–IFN-I axis, promoting host resistance to systemic viral infections.”
BackgroundRegulation of nucleotide metabolism in cancers and immune disorders
Ali, E. S., & Ben‐Sahra, I. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.03.003 · Cited by 146
Microbial Metabolites and Gut Immunology
Takeuchi, T., Nakanishi, Y., & Ohno, H. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-102035 · Cited by 146
Microbial transmission in the social microbiome and host health and disease
Sarkar, A., McInroy, C. J. A., Harty, S., Raulo, A., Ibata, N. G. O., Valles‐Colomer, M., Johnson, K. V. ‐., Brito, I., Henrich, J., Archie, E. A., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.014 · Cited by 151
The role of key gut microbial metabolites in the development and treatment of cancer
Jaye, K. M., Li, C. G., Chang, D., & Bhuyan, D. J. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2038865 · Cited by 140
“The proposed mechanism of action of inosine on bladder cancer was the enhancement of the function of anti-CTLA-4 to increase infiltration of IFN-ɣCD4 and IFN-ɣCD8 T-cells into the tumour, as well as reducing overall tumour weight when administered with CpG (DNA oligonucleotides containing unmethylated deoxycytidylyl-d…”
BackgroundMethodResultInfluentialThe gut microbiota promotes distal tissue regeneration via RORγ+ regulatory T cell emissaries
Hanna, B. S., Wang, G., Galván-Peña, S., Mann, A. O., Ramirez, R. N., Muñoz-Rojas, A. R., Smith, K., Wan, M., Benoist, C., & Mathis, D. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.033 · Cited by 126
Progress of engineered bacteria for tumor therapy
Fan, J., Niu, M., Qin, Y., Sun, Y., & Zhang, X. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114296 · Cited by 129
Sadrekarimi, H., Gardanova, Z. R., Bakhshesh, M., Ebrahimzadeh, F., Yaseri, A. F., Thangavelu, L. P., Hasanpoor, Z., Zadeh, F. A., & Kahrizi, M. S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03492-7 · Cited by 142
The gut microbiota in cancer immunity and immunotherapy
Xie, M., Li, X., Lau, H. C.-H., & Yu, J. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01326-2 · Cited by 138
“…and colleagues showed that the probiotic B. pseudolongum improves immunotherapy ef fi cacy through inosine production, but this process is dependent on ICB-induced dysfunction of the gut barrier, which allows systemic translocation of inosine and the subsequent activation of antitumor T cells [112].”
Influential
Metadata
- Authors
- Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., Lewis, I. A., Geuking, M. B., & McCoy, K. D.
- Affiliations
- University of Calgary (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Mager, Lukas F.
- McCoy, Kathy D.
- ORCID
- Venue
- Science
- Published
- 2020-09-18
- Volume
- 369
- Issue
- 6510
- Pages
- 1481-1489
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3049052172
- Semantic Scholar
- 041ece73120d89c36e2870fa3f1b95b4ebdafab2
- Cited by
- 1,407
- References
- 65
- Citations by year
- 2026: 240 · 2025: 280 · 2024: 260 · 2023: 247 · 2022: 220 · 2021: 134 · 2020: 25
- FWCI
- 56.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (PJT-165930, PJT-156073)
- Natural Sciences and Engineering Research Council of Canada
- Swiss National Science Foundation
- Alberta Innovates
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- inosine, gut microbiota, immune checkpoint inhibitors, cancer immunotherapy, antitumor immunity, microbial metabolites, T cell activation, colorectal cancer, bladder cancer, melanoma, immunotherapy response
- MeSH terms
- Gastrointestinal Microbiome, Lactobacillus johnsonii, Animals, Antibodies, Bifidobacterium, Urinary Bladder Neoplasms, Female, Immunotherapy, Inosine, Intestinal Neoplasms, Male, Melanoma, Mice, Inbred C57BL, Neoplasms, Experimental, Skin Neoplasms, T-Lymphocytes, Receptor, Adenosine A2A, Mice, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.